Guggenheim lowered the firm’s price target on IGM Biosciences to $25 from $38 and keeps a Buy rating on the shares after the company reported Q2 results and gave “an in-line business update.” The firm is updating its model and estimates to account for the company’s recent public offering and concurrent private placement of about 13.4M shares, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IGMS:
- IGM Biosciences reports Q2 EPS ($1.43), consensus ($1.43)
- IGM Biosciences Announces Second Quarter 2023 Financial Results
- Fly Insider: Children’s Place, Netflix among notable insider trades this week
- Biotech Alert: Searches spiking for these stocks today
- IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters’ Option to Purchase Additional Shares